Key regions: China, Europe, Australia, United States, Germany
The Other Pharmaceuticals market in Kazakhstan has been experiencing steady growth in recent years.
Customer preferences: Kazakhstan's population is aging, and as a result, there is an increasing demand for pharmaceutical products. This has led to a rise in demand for Other Pharmaceuticals, which includes all non-prescription drugs that are sold over the counter. Customers in Kazakhstan prefer to purchase these drugs from pharmacies, which are easily accessible and offer a wide range of products.
Trends in the market: One major trend in the Other Pharmaceuticals market in Kazakhstan is the increasing availability of generic drugs. These drugs are cheaper than their branded counterparts and are becoming more widely accepted by customers. Additionally, there has been a shift towards natural and herbal remedies, as customers are becoming more health-conscious and are looking for alternative treatments.
Local special circumstances: Kazakhstan is a large country with a relatively small population, which means that the market for pharmaceutical products is not as large as in other countries. However, the government has been investing in the healthcare sector and has made efforts to improve access to healthcare services in rural areas. This has led to an increase in demand for pharmaceutical products, including Other Pharmaceuticals.
Underlying macroeconomic factors: Kazakhstan's economy has been growing steadily in recent years, and this has had a positive impact on the pharmaceutical industry. The government has been investing in healthcare infrastructure and has made efforts to attract foreign investment in the sector. Additionally, the country's strategic location makes it an attractive market for pharmaceutical companies looking to expand their operations in Central Asia.In conclusion, the Other Pharmaceuticals market in Kazakhstan is growing steadily due to increasing customer demand, a shift towards generic and natural remedies, government investment in healthcare infrastructure, and a growing economy.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
